title: Outpatient treatment of pulmonary embolism is feasible and safe in a substantial proportion of patients.
authors.forename: J H
authors.initials: JH
authors.lastname: Beer
authors.forename: M
authors.initials: M
authors.lastname: Burger
authors.forename: S
authors.initials: S
authors.lastname: Gretener
authors.forename: S
authors.initials: S
authors.lastname: Bernard-Bagattini
authors.forename: H
authors.initials: H
authors.lastname: Bounameaux
mesh_terms: D000293:Adolescent; D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D000553:Ambulatory Care / Q000592:standards*; D000925:Anticoagulants / Q000627:therapeutic use; D005240:Feasibility Studies; D006495:Heparin, Low-Molecular-Weight / Q000627:therapeutic use; D006801:Humans; D008875:Middle Aged; D017762:Nadroparin / Q000627:therapeutic use; D010045:Outpatients; D010644:Phenprocoumon / Q000627:therapeutic use; D011655:Pulmonary Embolism / Q000188:drug therapy* / Q000453:epidemiology; D012306:Risk; D016896:Treatment Outcome
chemical_list: D000925:Anticoagulants; D006495:Heparin, Low-Molecular-Weight; D017762:Nadroparin; D010644:Phenprocoumon